Spectrum enters into license deal for Phase III PTCL drug

chemo NCI.jpg

TopoTarget has entered into a licensing deal with Spectrum Pharmaceuticals for Belinostat, TopoTarget's Phase III lymphoma drug.

The deal gives Spectrum an additional lymphoma-related product to go along with Zevalin.

Belinostat (PXD 101) was granted orphan drug status by the FDA in September 2009 for the treatment of peripheral t-cell lymphoma (PTCL). It is believed to work by blocking enzymes required for cell division and by stunting the development of blood vessels in tumors.

The drug is classed as a histone deacetylase inhibitor, an angiogenesis inhibitor, and a chemosensitizer. If all goes well, it could be available to PTCL patients in the US in late 2011.

By Ross Bonander

LymphomaInfo Social